Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
clinical trials
112
×
life sciences
national blog main
biotech
boston blog main
boston top stories
national top stories
fda
san francisco blog main
new york blog main
san francisco top stories
new york top stories
san diego blog main
national
san diego top stories
raleigh-durham blog main
indiana blog main
raleigh-durham top stories
indiana top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
drugs
cancer
startups
investing
eli lilly
amgen
gene therapy
novartis
pfizer
What
drug
medicines
fda
new
medicine
roundup
bio
ipo
therapeutics
approved
cancer
patients
disease
million
week
approval
biotech
clinical
companies
company
data
drugs
medical
raised
research
ago
science
treat
blood
days
developing
gene
genetic
life
market
nod
pharmaceuticals
plans
regulatory
therapy
Language
unset
Current search:
" clinical trials "
×
@techcrunch.com
1 year ago
Truveta is making progress towards building a living medical portrait of America
@techcrunch.com
1 year ago
BioNTech founder Uğur Şahin and Mayfield’s Ursheet Parikh are coming to Disrupt
@xconomy.com
2 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
2 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
2 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
2 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
2 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
2 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
2 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
2 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
2 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
2 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
2 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
2 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
2 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
2 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
3 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@venturebeat.com
3 years ago
Unlearn.ai raises $12 million to accelerate clinical trials with ‘digital twins’
@xconomy.com
3 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
3 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
3 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
3 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
3 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
3 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
3 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
3 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
3 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
3 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
3 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
3 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
3 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
3 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
3 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
3 years ago
DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs
@xconomy.com
3 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
3 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
3 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
3 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
3 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
3 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
3 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
3 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
3 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
3 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
3 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
First
Prev
Page 1
(current)
Next
Last